CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review

1. Van Acker H, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol 2017; 8: 892–90. doi: 10.3389/fimmu.2017.00892 Van AckerH CapsomidisA SmitsEL Van TendelooVF CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol 2017 8 892 90 10.3389/fimmu.2017.00892 Open DOISearch in Google Scholar

2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. 4^th edition. Lyon: IARC; 2017. SwerdlowSH CampoE HarrisNL JaffeES PileriSA SteinH WHO classification of tumours of hematopoietic and lymphoid tissues 4th edition Lyon IARC 2017 Search in Google Scholar

3. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based hemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43–7. doi: 10.1080/10428190500272549 ChangH SamieeS YiQL Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based hemotherapy and autologous stem cell transplant Leuk Lymphoma 2006 47 43 7 10.1080/10428190500272549 Open DOISearch in Google Scholar

4. Chaudhri NA, Almhareb F, Walter CU, Nounou R, Khalil S, Bakshi N, et al. Expression of CD56 in acute myeloid leukemia (AML) is associated with poor outcome when patients treated with stem cell transplant in second remission but not in the first remission. Blood 2011; 118: 4880–86. doi: 10.1182/blood.V118.21.4880.4880 ChaudhriNA AlmharebF WalterCU NounouR KhalilS BakshiN Expression of CD56 in acute myeloid leukemia (AML) is associated with poor outcome when patients treated with stem cell transplant in second remission but not in the first remission Blood 2011 118 4880 86 10.1182/blood.V118.21.4880.4880 Open DOISearch in Google Scholar

5. Ravandi F, Cortes J, Estrov Z, Thomas D. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukaemia. Leuk Res 2002; 26: 643–49. doi: 10.1016/s0145-2126(01)00188-6 RavandiF CortesJ EstrovZ ThomasD CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukaemia Leuk Res 2002 26 643 49 10.1016/s0145-2126(01)00188-6 Open DOISearch in Google Scholar

6. Grimma KE, O’Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol 2019; 38: 6–10. doi: 10.1016/j.anndiagpath.2018.09.014 GrimmaKE O’MalleyDP Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues Ann Diagn Pathol 2019 38 6 10 10.1016/j.anndiagpath.2018.09.014 Open DOISearch in Google Scholar

7. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the group d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117–26. doi: 10.1200/JCO.2005.09.131 FeugierP Van HoofA SebbanC Solal-CelignyP BouabdallahR FerméC Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the group d’Etude des Lymphomes de l’Adulte J Clin Oncol 2005 23 4117 26 10.1200/JCO.2005.09.131 Open DOISearch in Google Scholar

8. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification and treatment. Am J Hematol 2019; 94: 604–16. doi: 10.1002/ajh.25460 LiuY BartaSK Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification and treatment Am J Hematol 2019 94 604 16 10.1002/ajh.25460 Open DOISearch in Google Scholar

9. Gomyo H, Kajimoto K, Miyata Y, Maeda A, Mizuno I, Yamamoto K, et al. CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression. Hematology 2010; 15: 157–61. doi: 10.1179/102453309X12583347113573 GomyoH KajimotoK MiyataY MaedaA MizunoI YamamotoK CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression Hematology 2010 15 157 61 10.1179/102453309X12583347113573 Open DOISearch in Google Scholar

10. Gu MJ, Ha JO. CD56 positive diffuse large B-cell lymphoma: a case report and literature review. Int J Clin Exp Pathol 2013; 6: 3023–25. GuMJ HaJO CD56 positive diffuse large B-cell lymphoma: a case report and literature review Int J Clin Exp Pathol 2013 6 3023 25 Search in Google Scholar

11. Weisberger J, Gorczyca W, Kinney MC. CD56-Positive Large B-cell Lymphoma. App Imm Mol Morphol 2007; 14: 369–74. doi: 10.1097/01.pai.0000208279.66189.43 WeisbergerJ GorczycaW KinneyMC CD56-Positive Large B-cell Lymphoma App Imm Mol Morphol 2007 14 369 74 10.1097/01.pai.0000208279.66189.43 Open DOISearch in Google Scholar

12. Stacchini A, Barreca A, Demurtas A, Aliberti S, di Celle PF, Novero D. Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature. Histopathology 2012; 60: 452–59. doi: 10.1111/j.1365-2559.2011.04098.x StacchiniA BarrecaA DemurtasA AlibertiS di CellePF NoveroD Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature Histopathology 2012 60 452 59 10.1111/j.1365-2559.2011.04098.x Open DOISearch in Google Scholar

13. Isobe Y, Sugimoto K, Takeuchi K, Ando J, Masuda A, Mori T, et al. Neural cell adhesion molecule (CD56)-positive B-cell lymphoma. Eur J Haematol 2007; 79: 166–9. doi: 10.1111/j.1600-0609.2007.00893.x IsobeY SugimotoK TakeuchiK AndoJ MasudaA MoriT Neural cell adhesion molecule (CD56)-positive B-cell lymphoma Eur J Haematol 2007 79 166 9 10.1111/j.1600-0609.2007.00893.x Open DOISearch in Google Scholar

14. Otsuka M, Yakushijin Y, Hamada M, Hato T, Yasukawa M, Fujita S. Role of CD21 antigen in diffuse largeB-cell lymphoma and its clinical significance. Br J Hematol 2004; 127: 416–24. doi: 10.1111/j.1365-2141.2004.05226.x OtsukaM YakushijinY HamadaM HatoT YasukawaM FujitaS Role of CD21 antigen in diffuse largeB-cell lymphoma and its clinical significance Br J Hematol 2004 127 416 24 10.1111/j.1365-2141.2004.05226.x Open DOISearch in Google Scholar

15. Hammer RD, Vnencak-Jones CL, Manning B, Glick AD, Kinney MC. Microvillus lymphomas are B-cell neoplasms that frequently express CD56. Mod Pathol 1998; 11: 239–46. PMID: 9521469 HammerRD Vnencak-JonesCL ManningB GlickAD KinneyMC Microvillus lymphomas are B-cell neoplasms that frequently express CD56 Mod Pathol 1998 11 239 46 9521469 Search in Google Scholar

16. Chen B, Sun WY, Zhang G. [CD56 positive diffuse large B-cell lymphoma: report of a case]. [Chinese]. Zhonghua Bing Li Xue Za Zhi 2010; 39: 343–4. PMID: 20654160 ChenB SunWY ZhangG [CD56 positive diffuse large B-cell lymphoma: report of a case]. [Chinese] Zhonghua Bing Li Xue Za Zhi 2010 39 343 4 20654160 Search in Google Scholar

17. Muroi K, Omine K, Kuribara R, Uchida M, Izumi T, Hatake K, et al. CD56 expression in B-cell lymphoma. Leuk Res 1998; 22: 201–2. doi: 10.1016/s0145-2126(97)00153-7 MuroiK OmineK KuribaraR UchidaM IzumiT HatakeK CD56 expression in B-cell lymphoma Leuk Res 1998 22 201 2 10.1016/s0145-2126(97)00153-7 Open DOISearch in Google Scholar

18. Sekita T, Tamaru J, Isobe K, Harigaya K, Masuoka S, Katayama T, et al. Diffuse large B-cell lymphoma expressing the natural killer cell marker CD56. Pathol Int 1999; 49: 752–8. doi: 10.1046/j.1440-1827.1999.00929.x SekitaT TamaruJ IsobeK HarigayaK MasuokaS KatayamaT Diffuse large B-cell lymphoma expressing the natural killer cell marker CD56 Pathol Int 1999 49 752 8 10.1046/j.1440-1827.1999.00929.x Open DOISearch in Google Scholar

19. Boltezar L, Kloboves-Prevodnik V, Pohar-Perme M, Gasljevic G, Jezersek-Novakovic B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903–12. doi: 10.3892/ol.2018.8243 BoltezarL Kloboves-PrevodnikV Pohar-PermeM GasljevicG Jezersek-NovakovicB Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma Oncol Lett 2018 15 6903 12 10.3892/ol.2018.8243 Open DOISearch in Google Scholar

20. Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves-Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 191–6. doi: 10.1186/s13000-015-0427-5 BrozicA Pohar MarinsekZ NovakovicS Kloboves-PrevodnikV Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015 10 191 6 10.1186/s13000-015-0427-5 Open DOISearch in Google Scholar

21. Crotty R, Hu K, Stevenson K, Pontius MY, Sohani AR, Ryan RJH, et al. Simultaneous identification of cell of origin, translocations, and hotspot mutations in diffuse large B-cell lymphoma using a single RNA-sequencing assay. Am J Clin Pathol 2021; 155: 748–54. doi: 10.1093/ajcp/aqaa185 CrottyR HuK StevensonK PontiusMY SohaniAR RyanRJH Simultaneous identification of cell of origin, translocations, and hotspot mutations in diffuse large B-cell lymphoma using a single RNA-sequencing assay Am J Clin Pathol 2021 155 748 54 10.1093/ajcp/aqaa185 Open DOISearch in Google Scholar

22. Mokánszki A, Bicskó R, Gergely L, Méhes G. Cell-free total nucleic acid-based genotyping of aggressive lymphoma: Comprehensive analysis of gene fusions and nucleotide variants by next-generation sequencing. Cancers 2021; 13: 3032. doi: 10.3390/cancers13123032 MokánszkiA BicskóR GergelyL MéhesG Cell-free total nucleic acid-based genotyping of aggressive lymphoma: Comprehensive analysis of gene fusions and nucleotide variants by next-generation sequencing Cancers 2021 13 3032 10.3390/cancers13123032 Open DOISearch in Google Scholar

23. Kern WF, Spier CM, Miller TP, Grogan TM. NCAM (CD56)-positive malignant lymphoma. Leuk Lymphoma 1993; 12: 1–10. doi: 10.3109/10428199309059565 KernWF SpierCM MillerTP GroganTM NCAM (CD56)-positive malignant lymphoma Leuk Lymphoma 1993 12 1 10 10.3109/10428199309059565 Open DOISearch in Google Scholar

24. Kirpatrik D, Swalling A, Kasmeridis H, Farshid G. Metastatic neuroendocrine carcinoma negative for cytokeratin immunohistochemistry. Pathology 2017; S1: S140–S141. doi: 10.1016/j.pathol.2016.09.057 KirpatrikD SwallingA KasmeridisH FarshidG Metastatic neuroendocrine carcinoma negative for cytokeratin immunohistochemistry Pathology 2017 S1 S140 S141 10.1016/j.pathol.2016.09.057 Open DOISearch in Google Scholar

25. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–82. doi: 10.1182/blood-2003-05-1545 HansCP WeisenburgerDD GreinerTC GascoyneRD DelabieJ OttG Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 2004 103 275 82 10.1182/blood-2003-05-1545 Open DOISearch in Google Scholar

26. Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; 31: 1579–83. doi: 10.1016/j.leukres.2007.03.017 ShiozawaE Yamochi-OnizukaT TakimotoM OtaH The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries Leuk Res 2007 31 1579 83 10.1016/j.leukres.2007.03.017 Open DOISearch in Google Scholar

27. Rutishauer U, Acheson A, Hall AK, Mann DM, Sunshine J. The neural adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science 1988; 240: 53–7. doi: 10.1126/science.3281256 RutishauerU AchesonA HallAK MannDM SunshineJ The neural adhesion molecule (NCAM) as a regulator of cell-cell interactions Science 1988 240 53 7 10.1126/science.3281256 Open DOISearch in Google Scholar

28. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CMCD56). J Immunol 1991; 146: 4421–26. LanierLL ChangC AzumaM RuitenbergJJ HemperlyJJ PhillipsJH Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CMCD56) J Immunol 1991 146 4421 26 Search in Google Scholar

29. Young HE, Steele TA, Bray RA, Detmer K, Blake LW, Lucas PW, et al. Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I. Proc Soc Exp Biol Med 1999; 221: 63–71. doi: 10.1046/j.1525-1373.1999.d01-55.x YoungHE SteeleTA BrayRA DetmerK BlakeLW LucasPW Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I Proc Soc Exp Biol Med 1999 221 63 71 10.1046/j.1525-1373.1999.d01-55.x Open DOISearch in Google Scholar

30. Navarrete M, Oppezzo P. The pathogenesis of follicular lymphoma beyond apoptosis resistance. Trans Canc Res 2017; 6: S529–S532. doi: 10.21037/tcr.201 NavarreteM OppezzoP The pathogenesis of follicular lymphoma beyond apoptosis resistance Trans Canc Res 2017 6 S529 S532 10.21037/tcr.201 Open DOISearch in Google Scholar

31. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373–80. doi: 10.1200/JCO.2009.26.2493 ZiepertM HasencleverD KuhntE GlassB SchmitzN PfreundschuhM Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 2010 28 2373 80 10.1200/JCO.2009.26.2493 Open DOISearch in Google Scholar

32. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. NEJM 2018; 378: 1396–407. doi: 10.1056/NEJMoa1801445. SchmitzR WrightGW HuangDW JohnsonCA PhelanJD WangJQ Genetics and pathogenesis of diffuse large B-cell lymphoma NEJM 2018 378 1396 407 10.1056/NEJMoa1801445 Open DOISearch in Google Scholar

33. Shah MH, Lorigan P, O’Brien MER, Fossella FV, Moore KN, Bhatia S, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumours. Invest New Drugs 2016; 34: 290–99. doi: 10.1007/s10637-016-0336-9. ShahMH LoriganP O’BrienMER FossellaFV MooreKN BhatiaS Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumours Invest New Drugs 2016 34 290 99 10.1007/s10637-016-0336-9 Open DOISearch in Google Scholar

34. Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, et al. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SLCL models. Oncogene 2018; 37: 3686–97. doi:10.1038/s41388-018-0187-2 CrosslandDL DenningWL AngS OlivaresS MiT SwitzerK Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SLCL models Oncogene 2018 37 3686 97 10.1038/s41388-018-0187-2 Open DOISearch in Google Scholar